Tavexia Lifecare Approves ₹67.19 Crore Meyonex Pharmaceuticals Acquisition

Board approved acquiring 60% of Meyonex Pharmaceuticals via 2,09,97,180 fresh shares at Rs32 for Rs67.2cr cash, and in-principle fundraise via preferential/rights issue to fund it. Targets controlling pharma stake for expansion, non-related party, subject to shareholder, statutory approvals and definitive agreements; fundraise quantum, price, timing to be set later. Creates dilution, execution and funding overhang; target FY25 turnover ~10.8cr vs FY24 ~13.3cr; valuation basis, profitability and completion timeline not disclosed.